Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

BACKGROUND: Although low-grade serous ovarian cancer (LGSC) is rare, case-fatality rates are high as most patients present with advanced disease and current cytotoxic therapies are not overly effective. Recognizing that these cancers may be driven by MAPK pathway activation, MEK inhibitors (MEKi) ar...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Cell Int
Autori principali: Fernandez, Marta Llaurado, Dawson, Amy, Hoenisch, Joshua, Kim, Hannah, Bamford, Sylvia, Salamanca, Clara, DiMattia, Gabriel, Shepherd, Trevor, Cremona, Mattia, Hennessy, Bryan, Anderson, Shawn, Volik, Stanislav, Collins, Colin C., Huntsman, David G., Carey, Mark S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Primary Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6325847/
https://ncbi.nlm.nih.gov/pubmed/30636931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-019-0725-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi